Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives
Abstract Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin’s lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patie...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-01-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-024-00989-w |
| _version_ | 1827369991650934784 |
|---|---|
| author | Iman Abou Dalle Remy Dulery Nour Moukalled Laure Ricard Nicolas Stocker Jean El-Cheikh Mohamad Mohty Ali Bazarbachi |
| author_facet | Iman Abou Dalle Remy Dulery Nour Moukalled Laure Ricard Nicolas Stocker Jean El-Cheikh Mohamad Mohty Ali Bazarbachi |
| author_sort | Iman Abou Dalle |
| collection | DOAJ |
| description | Abstract Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin’s lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patients, whereas the other half will have a dismal outcome with a median overall survival of less than 12 months. This unmet need reinforced the importance of innovative therapies like the BsAbs and CAR-T cell therapies. In this review, we delve into BsAbs in B-NHL from the preclinical development to clinical data in both refractory and frontline settings, and then discuss future perspectives. |
| first_indexed | 2024-03-08T10:00:46Z |
| format | Article |
| id | doaj.art-59c6a495ec6f48fba563a4576b058f13 |
| institution | Directory Open Access Journal |
| issn | 2044-5385 |
| language | English |
| last_indexed | 2024-03-08T10:00:46Z |
| publishDate | 2024-01-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj.art-59c6a495ec6f48fba563a4576b058f132024-01-29T10:59:08ZengNature Publishing GroupBlood Cancer Journal2044-53852024-01-0114111110.1038/s41408-024-00989-wBi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectivesIman Abou Dalle0Remy Dulery1Nour Moukalled2Laure Ricard3Nicolas Stocker4Jean El-Cheikh5Mohamad Mohty6Ali Bazarbachi7Hematology-Oncology Division, American University of Beirut Medical CenterSorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938Hematology-Oncology Division, American University of Beirut Medical CenterSorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938Hematology-Oncology Division, American University of Beirut Medical CenterSorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938Hematology-Oncology Division, American University of Beirut Medical CenterAbstract Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin’s lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patients, whereas the other half will have a dismal outcome with a median overall survival of less than 12 months. This unmet need reinforced the importance of innovative therapies like the BsAbs and CAR-T cell therapies. In this review, we delve into BsAbs in B-NHL from the preclinical development to clinical data in both refractory and frontline settings, and then discuss future perspectives.https://doi.org/10.1038/s41408-024-00989-w |
| spellingShingle | Iman Abou Dalle Remy Dulery Nour Moukalled Laure Ricard Nicolas Stocker Jean El-Cheikh Mohamad Mohty Ali Bazarbachi Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives Blood Cancer Journal |
| title | Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives |
| title_full | Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives |
| title_fullStr | Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives |
| title_full_unstemmed | Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives |
| title_short | Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives |
| title_sort | bi and tri specific antibodies in non hodgkin lymphoma current data and perspectives |
| url | https://doi.org/10.1038/s41408-024-00989-w |
| work_keys_str_mv | AT imanaboudalle biandtrispecificantibodiesinnonhodgkinlymphomacurrentdataandperspectives AT remydulery biandtrispecificantibodiesinnonhodgkinlymphomacurrentdataandperspectives AT nourmoukalled biandtrispecificantibodiesinnonhodgkinlymphomacurrentdataandperspectives AT laurericard biandtrispecificantibodiesinnonhodgkinlymphomacurrentdataandperspectives AT nicolasstocker biandtrispecificantibodiesinnonhodgkinlymphomacurrentdataandperspectives AT jeanelcheikh biandtrispecificantibodiesinnonhodgkinlymphomacurrentdataandperspectives AT mohamadmohty biandtrispecificantibodiesinnonhodgkinlymphomacurrentdataandperspectives AT alibazarbachi biandtrispecificantibodiesinnonhodgkinlymphomacurrentdataandperspectives |